Use of angiogenesis inhibitors in tumour treatment.
Advances in molecular biology have permitted the characterisation of mechanisms underlying angiogenesis. Angiogenesis is a crucial process in tumour pathogenesis as it sustains malignant cells with nutrients and oxygen. It is well known that tumour cells secrete various growth factors including VEGF, which triggers endothelial cells to form new capillaries. Preventing the expansion of new blood vessel networks results in reduced tumour size and metastases. Not surprisingly, numerous drugs that are currently under clinical development interfere with growth factor-derived angiogenic signals. This review aims to describe angiogenesis inhibitors and surveys their different modes of action.
Fayette
Jérôme
J
Institut Gustave Roussy, Département de Médecine, 39 Rue Camille Desmoulins, 94805 Villejuif, France.
Soria
Jean-Charles
JC
Armand
Jean-Pierre
JP
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D042461:Vascular Endothelial Growth Factor A